Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in PV patients. AOP2014 induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden Click here for the complete article Details on the clinical trial […]
